6 results about "Nucleic acid hybridisation" patented technology

A CRISPR-Cas system and applications thereof are provided, also related to a Cas protein, a fusion protein and a guide polynucleotide. The Cas protein has at least 50% sequence identity compared to the sequence set forth in any one of SEQ ID NOs: 1-184, 426-428. The fusion protein comprises the Cas protein fused to a protein domain and / or a polypeptide tag. The guide polynucleotide comprises a direct repeat sequence having at least 70% sequence identity to any one of SEQ ID NOs: 185-199, 245-247, 287-303, 369 and 370-373, and a guide sequence engineered to hybridize to a target nucleic acid. The CRISPR-Cas system comprises a Cas protein having at least 90% sequence identity compared to the sequence set forth in any one of SEQ ID NOs: 1-184, 426-428, or a nucleic acid encoding thereof, and a guide polynucleotide or a nucleic acid encoding thereof.

Provided herein are methods, compositions, and kits for the spatial analysis of target nucleic acids in biological samples by their 5′ end. An exemplary method includes: contacting a biological sample with a primer that hybridizes the target nucleic acid; hybridizing the primer to the target nucleic acid and extending using the target nucleic acid as a template to generate an extension product; incorporating a non-templated polynucleotide sequence including at least three nucleotides to the 3′ end of the extension product; hybridizing the polynucleotide sequence of the extension product to a capture domain on an array including a plurality of capture probes that include a spatial barcode and the capture domain; and determining the spatial barcode sequence, or complement thereof, and all or a portion of the extension product, or complement thereof, and using the determined sequences to determine the location of the target nucleic acid in the biological sample. The non-templated polynucleotide sequence may be C-C-C or C-G-C introduced by terminal transferase or may be introduced by SMART technology using reverse transcriptase.

This invention relates to the field of biosensors and microfluidics, and particularly to a method for treating interfering DNA based on an ultrasonic-driven device. The method includes an ultrasonic-driven device comprising a piezoelectric substrate, Rayleigh wave drive, microfluidic reaction, and drive control module. First, a nucleic acid hybridization system is constructed to achieve initial binding and recognition of interfering DNA. Then, Rayleigh waves are excited to generate physical shearing force. Based on the difference in binding force between the interfering DNA and the target DNA and probe, precise mechanical feature recognition is achieved. By adjusting the radio frequency signal parameters to make the shearing force between the two types of binding forces, the interfering DNA is dissociated and expelled, completing the selective removal process.

Binding complexes including a detectable nucleotide conjugate having a plurality of copies of a nucleotide attached to the particle are described. The binding complexes allow one to localize detectable signals to active regions of biochemical interaction, e.g., sites of protein-protein interaction, protein-nucleic acid interaction, nucleic acid hybridization, or enzymatic reaction, and can be used to identify sites of base incorporation in elongating nucleic acid chains during polymerase reactions and to provide improved base discrimination for sequencing and array-based applications.

A method includes inserting a fluid including a sample into a cartridge, lysing the sample in an extraction chamber to release nucleic acids of interest from the sample, collecting a first set of hybridized magnetic particles hybridized to a first type of nucleic acids of interest by: hybridizing the first type of nucleic acids of interest with an oligonucleotide attached to magnetic particles, holding the first set of hybridized magnetic particles on a side of the extraction chamber, suspending the first set of hybridized magnetic particles with a wash buffer, transporting the first set of hybridized magnetic particles to a detection chamber, collecting a second set of hybridized magnetic particles hybridized to a second type of nucleic acids of interest, amplifying the sets of hybridized magnetic particles, and detecting a plurality of amplification products indicative of the presence, absence, or amount of the types of nucleic acids of interest.

Provided are compositions, kits, and methods that can be used to selectively amplify a first target nucleic acid that is distinguishable from a second target nucleic acid, where the two target nucleic acids have both common and different sequence domains. Structured primers useful in the amplification method include 5′ and 3′ target-hybridizing sequences separated from each other by a joining region that does not hybridize to the target nucleic acid. Polymerase-based extension of the structured primer depends on specific hybridization of the 5′ sequence of the primer, thereby facilitating hybridization and extension of the 3′ sequence of the primer.